Quanli Gao

Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study

Yuqin Song, Quanli Gao, Huilai Zhang et al. · Leukemia · 2019 · 153 citations · Full text

Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant

Cheng Zhang, Xiaoqi Wang, Rongli Zhang et al. · Leukemia · 2020 · 77 citations · Full text

TGF-β blockade-improved chemo-immunotherapy with pH/ROS cascade-responsive micelle via tumor microenvironment remodeling

Liangliang Dai, Xiang Li, Xinmin Zheng et al. · Biomaterials · 2021 · 52 citations

Tgf-β Blockade-improved Chemo-immunotherapy, Cancer Immunosurveillance, Immunology +8

Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma

Lu Han, Jishuai Zhang, Jian Zhou et al. · Leukemia · 2021 · 50 citations · Full text

Hematological Malignancy, Medicine, Immunology +8

The phase I clinical study of CART targeting BCMA with humanized alpaca-derived single-domain antibody as antigen recognition domain.

Lu Han, Quanli Gao, Keshu Zhou et al. · Journal of Clinical Oncology · 2019 · 31 citations

Clinical Immunology, Immunology, Antigen Recognition Domain +26